4503 Share Price Performance
JP¥0
-1435.00 (-100.00%)
Price JP¥0
Fair ValueJP¥2,407.14
Share Pricen/a
Astellas Pharma Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
4503 Community Narratives
AN
Fair Value
·Fair Value JP¥2.41k 4.8% undervalued intrinsic discount
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value JP¥1.5k 52.8% overvalued intrinsic discount
Patent Expirations And Price Reforms Will Erode Future Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value JP¥2.95k 22.3% undervalued intrinsic discount
Global Aging And Personalized Medicine Will Open Therapeutic Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
Key Takeaways Strategic brands and pipeline momentum, especially in oncology and rare diseases, are driving revenue growth, supported by global demand in expanding and aging populations. Cost optimization and accelerated R&D productivity are enhancing profitability, with partnerships and emerging market uptake offering further upside to future earnings.Read more
AN
JP¥2.41k
4.8% undervalued intrinsic discount
Fair Value
Revenue
-3.5% p.a.
Profit Margin
12.01%
Future PE
22.36x
Price in 2029
JP¥2.77k
Global Aging And Personalized Medicine Will Open Therapeutic Markets
Key Takeaways Outperformance by key brands and rapid global market expansion suggest potential upside to revenue and long-term growth as adoption and market penetration accelerate. Faster-than-expected cost reductions and advanced R&D strategies are increasing profitability and positioning Astellas for leadership in innovative, high-value therapeutics.Read more
AN
JP¥2.95k
22.3% undervalued intrinsic discount
Fair Value
Revenue
-0.53% p.a.
Profit Margin
12.52%
Future PE
24x
Price in 2029
JP¥3.4k
Patent Expirations And Price Reforms Will Erode Future Margins
Key Takeaways Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability and hinder the replacement of expiring blockbusters. Pricing pressures, regulatory risks, and supply chain complexities increase margin volatility and operational uncertainty across key global markets.Read more
AN
JP¥1.5k
52.8% overvalued intrinsic discount
Fair Value
Revenue
-8.07% p.a.
Profit Margin
9.55%
Future PE
20.27x
Price in 2029
JP¥1.73k
Trending Discussion
Recently Updated Narratives
AN
4503: Bladder Cancer Data And Guidance Will Temper Risks From Weaker Legacy Portfolio
Fair Value: JP¥2.41k 4.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4503: Future Oncology Pipeline And Partnerships Will Support Upside Potential
Fair Value: JP¥2.95k 22.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4503: Trial Setbacks And Weaker Margins Will Likely Pressure Future Returns
Fair Value: JP¥1.5k 52.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Astellas Pharma Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 162.73
- 80.91%
- 13.63%
- 30.9%
About 4503
- Founded
- 1923
- Employees
- 13643
- CEO
- WebsiteView website
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.